{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:50:58Z","timestamp":1791355858992,"version":"4.3.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2013,9,3]]},"DOI":"10.1038\/bjc.2013.381","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T20:00:15Z","timestamp":1374004815000},"page":"1287-1290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study"],"prefix":"10.1038","volume":"109","author":[{"given":"S","family":"Beiggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J B","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M D","family":"Seftel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M W","family":"Pitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"J Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S B","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,16]]},"reference":[{"issue":"3","key":"BFbjc2013381_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/PAT.0b013e32835f515c","volume":"45","author":"AC Chen","year":"2013","unstructured":"Chen AC, Halliday GM, Damian DL (2013) Non-melanoma skin cancer: carcinogenesis and chemoprevention. Pathology 45 (3): 331\u2013341.","journal-title":"Pathology"},{"key":"BFbjc2013381_CR2","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O\u2019Brien S, Rai KR (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990\u20134997.","journal-title":"Blood"},{"key":"BFbjc2013381_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94: 496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"BFbjc2013381_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.2340\/00015555-1525","volume":"93","author":"JB Garc\u00eda","year":"2013","unstructured":"Garc\u00eda JB, Su\u00e1rez-Varela MM, Vilata JJ, Marquina A, Pallard\u00f3 L, Crespo J (2013) Risk factors for non-melanoma skin cancer in kidney transplant patients in a Spanish population in the Mediterranean region. Acta Derm Venereol 93: 422\u2013427.","journal-title":"Acta Derm Venereol"},{"key":"BFbjc2013381_CR5","first-page":"337","volume":"61","author":"MH Greene","year":"1978","unstructured":"Greene MH, Hoover RN, Fraumeni JF Jr (1978) Subsequent cancer in patients with chronic lymphocytic leukemia\u2014a possible immunologic mechanism. J Natl Cancer Inst 61: 337\u2013340.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2013381_CR6","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446\u20135456.","journal-title":"Blood"},{"key":"BFbjc2013381_CR7","first-page":"2256","volume-title":"Wintrobe\u2019s Clinical Hematology","author":"JB Johnston","year":"2009","unstructured":"Johnston JB, Gibson SB, Seftel MD (2009) Chronic lymphocytic leukemia. In: Greer JP, Foerster J, Lukens J, Paraskevas F, Rodgers GM, Glader B, (eds) Wintrobe\u2019s Clinical Hematology. Lippincott Williams & Wilkins: Baltimore, pp 2256\u20132275."},{"key":"BFbjc2013381_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/oxfordjournals.aje.a115387","volume":"130","author":"MS Linet","year":"1989","unstructured":"Linet MS, Van Natta ML, Brookmeyer R, Khoury MJ, McCaffrey LD, Humphrey RL, Szklo M (1989) Familial cancer history and chronic lymphocytic leukemia. A case-control study. Am J Epidemiol 130: 655\u2013664.","journal-title":"Am J Epidemiol"},{"key":"BFbjc2013381_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.1975.03250030023012","volume":"232","author":"D Manusow","year":"1975","unstructured":"Manusow D, Weinerman BH (1975) Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 232: 267\u2013269.","journal-title":"JAMA"},{"key":"BFbjc2013381_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/10428190400007524","volume":"46","author":"S Molica","year":"2005","unstructured":"Molica S (2005) Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies. Leuk Lymphoma 46: 49\u201354.","journal-title":"Leuk Lymphoma"},{"key":"BFbjc2013381_CR11","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","volume":"28","author":"LM Morton","year":"2010","unstructured":"Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LAG, Fraumeni JF Jr (2010) Second malignancy risks after non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 28: 4935\u20134944.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013381_CR12","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1158\/1055-9965.EPI-05-0379","volume":"14","author":"Z Nugent","year":"2005","unstructured":"Nugent Z, Demers AA, Wiseman MC, Mihalcioiu C, Kliewer EV (2005) Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 14: 2584\u20132590.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFbjc2013381_CR13","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/bjc.2011.313","volume":"105","author":"JA Royle","year":"2011","unstructured":"Royle JA, Baade PD, Joske D, Girschik J, Fritschi L (2011a) Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer 105: 1076\u20131081.","journal-title":"Br J Cancer"},{"key":"BFbjc2013381_CR14","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ijc.25706","volume":"129","author":"JS Royle","year":"2011","unstructured":"Royle JS, Baade P, Joske D, Fritschi L (2011b) Risk of second cancer after lymphohematopoietic neoplasm. Int J Cancer 129: 910\u2013919.","journal-title":"Int J Cancer"},{"key":"BFbjc2013381_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ijc.22672","volume":"121","author":"C Sch\u00f6llkopf","year":"2007","unstructured":"Sch\u00f6llkopf C, Rosendahl D, Rostgaard K, Pipper C, Hjalgrim H (2007) Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer 121: 151\u2013156.","journal-title":"Int J Cancer"},{"key":"BFbjc2013381_CR16","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.leukres.2009.06.013","volume":"33","author":"MD Seftel","year":"2009","unstructured":"Seftel MD, Demers AA, Banerji V, Gibson SB, Morales C, Musto G, Pitz MW, Johnston JB (2009) High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: a population-based Canadian cohort. Leuk Res 33: 1463\u20131468.","journal-title":"Leuk Res"},{"key":"BFbjc2013381_CR17","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1200\/JCO.2012.43.4449","volume":"31","author":"BM Solomon","year":"2013","unstructured":"Solomon BM, Rabe KG, Slager SL, Brewer JD, Cerhan JR, Shanafelt TD (2013) Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol 31: 930\u2013937.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013381_CR18","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1080\/1042819021000002956","volume":"43","author":"J Teruya-Feldstein","year":"2002","unstructured":"Teruya-Feldstein J, Greene J, Cohen L, Popplewell L, Ellis NA, Offit K (2002) Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer. Leuk Lymphoma 43: 1619\u20131626.","journal-title":"Leuk Lymphoma"},{"key":"BFbjc2013381_CR19","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.1182\/blood-2009-08-237651","volume":"114","author":"H-T Tsai","year":"2009","unstructured":"Tsai H-T, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, Marti GE, Albitar M, Ghia P, Rajkumar SV, Landgren O (2009) Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood 114: 4928\u20134932.","journal-title":"Blood"},{"key":"BFbjc2013381_CR20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1200\/JCO.2008.17.5398","volume":"27","author":"A-M Tsimberidou","year":"2009","unstructured":"Tsimberidou A-M, Wen S, McLaughlin P, O\u2019Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ (2009) Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma. J Clin Oncol 27: 904\u2013910.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013381_CR21","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1200\/JCO.2008.18.1701","volume":"27","author":"WG Wierda","year":"2009","unstructured":"Wierda WG, O\u2019Brien S, Wang X, Faderl S, Ferrajoli A, Do K-A, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M (2009) Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 27: 1637\u20131643.","journal-title":"J Clin Oncol"},{"issue":"9","key":"BFbjc2013381_CR22","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.3109\/10428194.2012.666662","volume":"53","author":"J-Y Yoon","year":"2012","unstructured":"Yoon J-Y, Lafarge S, Dawe D, Lakhi S, Kumar R, Morales C, Marshall A, Gibson SB, Johnston JB (2012) Association of interleukin-6 and interleukin-8 with poor prognosis in elderly chronic lymphocytic leukemia patients. Leuk Lymphoma 53 (9): 1735\u20131742.","journal-title":"Leuk Lymphoma"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bjc2013381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bjc2013381","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bjc2013381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T17:02:35Z","timestamp":1727456555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2013381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,16]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9,3]]}},"alternative-id":["BFbjc2013381"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2013.381","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,16]]},"assertion":[{"value":"22 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2013","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"James Johnston is on the advisory board of Roche and received research funding from Roche Pharmaceuticals. Rajat Kumar is on the advisory board of Celgene. Other authors have no disclaimers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}